Andrew Renison is an Associate with Finnegan. His chemistry and life sciences practice focuses on U.S. district court litigation with a particular emphasis on pharmaceutical patents and Hatch-Waxman litigation. His experience ranges from pre-litigation analysis through trial in large, complex ANDA litigation. Andrew’s practice also includes strategic counseling and patent prosecution covering a range of technologies for clients in various industries.
Andrew’s litigation experience includes conducting pre-filing investigations, coordinating fact and expert discovery, taking and defending depositions, working with experts, managing day-to-day litigation activities, preparing for and going to trial and drafting post-trial briefing.
Andrew’s technical experience focused on the production and performance-testing of metal alloys ceramics. He was a recipient of the Metallurgy Trust Fund Scholarship. While earning his undergraduate degree, he worked on the synthesis and characterization of manganese dioxide nanorods at the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland.
The U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) recently released an update to its Orange Book patent and biologic patent study, examining post-grant petitions filed against Orange Book patents and biologic patents between September 16, 2012, and June 30, 2021. The PTAB classified a petition as challenging an Orange Book-listed patent by comparing the petition’s filing date with data from the U.S. Food and Drug Administration’s (FDA’s) electronic Orange Book indicating when the patent was listed. The PTAB manually identified biologic patents as any patent potentially covering a Purple Book-listed product and any non-Orange Book-listed patent directed to treating a disease or condition.